
SenzaGen Q2 - Continued sales growth

Redeye provides an update following SenzaGen's Q2 2024 report. Sales continue to grow steadily; however, a bit under our estimate. We make some minor sales estimate changes, resulting in an updated fair value range. Concludingly, we argue that the investment case is intact and that the share is currently traded at attractive levels.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[SenzaGen Q2 - Continued sales growth](#)